Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 14 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 14746
Sealed predictions
- MYH9 in dopamine neurons, braak-0.47 (p 0.197) → +0.11 (p 0.775)receipt 14753
Swarm cases
receipt 14753: MYH9 in dopamine neurons, braak
- power
- full sample -0.32 (p 0.198, n 18), 95% CI -0.68 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.258, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.049, n 18). not the mix.
- skeptic
- leave-one-out range -0.42 to -0.24, sign flips 0; without severely affected donors -0.32 (p 0.198, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.71 (p 0.0010, n 18) vs -0.32 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MYH9 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MYH9 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 1.6e-4)
Receipts
loading the receipts